logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics appoints independent director from US partner company

He is Dr Steven Romano, the chief scientific officer at Mallinckrodt Pharmaceuticals, who has also held senior roles Pfizer and Eli Lilly

1564383584_boardroom-2.jpg
Dr Steven Romano will be a new face around the Silence board table

Silence Therapeutics PLC (LON:SLN) has announced the appointment of an independent director from its new partner, New York-listed specialty pharma group Mallinckrodt (NYSE:MKN).

He is Dr Steven Romano, the chief scientific officer at Mallinckrodt Pharmaceuticals, who has also held senior roles Pfizer and Eli Lilly.

“With his executive responsibility for research and development, medical affairs and regulatory affairs functions at Mallinckrodt, Steve brings wealth of experience that is highly relevant to the current stages of development of Silence's assets," said Silence chief executive David Horn Solomon.

Earlier this month Silence agreed a partnership with Mallinckrodt to develop and commercialise gene silencing treatments for serious diseases worth an upfront US$20mln.

Quick facts: Silence Therapeutics PLC

Price: 240 GBX

AIM:SLN
Market: AIM
Market Cap: £187.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

3 weeks ago

2 min read